中国生物制药(01177.HK)四代EGFR抑制剂获美国临床试验许可

阿斯达克财经
15 Nov 2024

中国生物制药(01177.HK) 公布,集团自主研发的四代EGFR抑制剂“TQB3002”正式获得美国食品药品监督管理局(FDA)的临床试验申请许可,即将启动I期临床试验。TQB3002通过与胞内酪氨酸激酶结合域的ATP位点竞争性结合,抑制相关酪氨酸激酶活性和细胞内磷酸化过程,进而抑制表皮生长因子受体下游的信号传导,最终导致肿瘤细胞死亡。(de/d)(港股报价延迟最少十五分钟。沽空资料截至 2024-11-14 16:25。)

AASTOCKS新闻

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10